Adverse drug events observed with intrathecal magnesium sulfate as an adjuvant to bupivacaine for spinal anesthesia in patients undergoing elective cesarean section: a meta-analysis.

IF 2.8 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Yuanhui Zhang, Yan Huang, Jun Li
{"title":"Adverse drug events observed with intrathecal magnesium sulfate as an adjuvant to bupivacaine for spinal anesthesia in patients undergoing elective cesarean section: a meta-analysis.","authors":"Yuanhui Zhang, Yan Huang, Jun Li","doi":"10.1186/s40360-025-00933-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Today, the number of cesarean section has drastically increased. Newer scientific reports have shown Magnesium sulfate (MgSO4) to have favorable outcomes for anesthesia. In this analysis, we aimed to systematically compare the adverse drug events observed with intrathecal MgSO4 as an adjuvant to bupivacaine for spinal anesthesia in patients undergoing elective cesarean section.</p><p><strong>Methods: </strong>MEDLINE, EMBASE, Web of Science, Google scholar, http://www.</p><p><strong>Clinicaltrials: </strong>gov , and the Cochrane database were searched for relevant publications comparing the adverse drug events observed with intrathecal MgSO4 as an adjuvant to bupivacaine for spinal anesthesia in patients undergoing elective cesarean section. The RevMan software version 5.4 was used to analyze data in this analysis. Risk ratios (RR) with 95% confidence intervals (CIs) were used to represent analysis for the dichotomous data whereas weighted mean difference (WMD) with 95% CI was used to represent results using continuous data. Heterogeneity was assessed by the Q statistic and the I2 statistic tests.</p><p><strong>Results: </strong>Eleven studies with a total number of 895 participants were included in this analysis whereby 466 patients were assigned to intrathecal MgSO4 and 429 participants were assigned to a control group. The main results of this analysis show that intrathecal MgSO4 as an adjuvant to bupivacaine was associated with a significantly lower risk of shivering (RR: 0.63, 95% CI: 0.48 - 0.83; P = 0.001). In addition, the risks for hypotension (RR: 1.11, 95% CI: 0.86 - 1.44; P = 0.40), nausea and vomiting (RR: 1.08, 95% CI: 0.76 - 1.54; P = 0.65), pruritus (RR: 0.77, 95% CI: 0.51 - 1.17; P = 0.22), and bradycardia (RR: 4.45, 95% CI: 0.97 - 20.36; P = 0.05) were not significantly increased. The sensory (WMD: 23.15, 95% CI: 7.83 - 38.48; P = 0.003), and motor block duration (WMD: 24.29, 95% CI: 16.36 - 32.23; P = 0.00001) and the duration of spinal anesthesia (WMD: 29.24, 95% CI: 13.61 - 44.87; P = 0.0002) were significantly in favor of MgSO4.</p><p><strong>Conclusion: </strong>Intrathecal MgSO4 as an adjuvant to bupivacaine was associated with a significantly lower risk of shivering without causing any increase in other adverse drug events in patients undergoing elective cesarean section. Efficacy outcomes were also appreciated. Larger studies should be able to confirm this hypothesis.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"96"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054056/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40360-025-00933-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Today, the number of cesarean section has drastically increased. Newer scientific reports have shown Magnesium sulfate (MgSO4) to have favorable outcomes for anesthesia. In this analysis, we aimed to systematically compare the adverse drug events observed with intrathecal MgSO4 as an adjuvant to bupivacaine for spinal anesthesia in patients undergoing elective cesarean section.

Methods: MEDLINE, EMBASE, Web of Science, Google scholar, http://www.

Clinicaltrials: gov , and the Cochrane database were searched for relevant publications comparing the adverse drug events observed with intrathecal MgSO4 as an adjuvant to bupivacaine for spinal anesthesia in patients undergoing elective cesarean section. The RevMan software version 5.4 was used to analyze data in this analysis. Risk ratios (RR) with 95% confidence intervals (CIs) were used to represent analysis for the dichotomous data whereas weighted mean difference (WMD) with 95% CI was used to represent results using continuous data. Heterogeneity was assessed by the Q statistic and the I2 statistic tests.

Results: Eleven studies with a total number of 895 participants were included in this analysis whereby 466 patients were assigned to intrathecal MgSO4 and 429 participants were assigned to a control group. The main results of this analysis show that intrathecal MgSO4 as an adjuvant to bupivacaine was associated with a significantly lower risk of shivering (RR: 0.63, 95% CI: 0.48 - 0.83; P = 0.001). In addition, the risks for hypotension (RR: 1.11, 95% CI: 0.86 - 1.44; P = 0.40), nausea and vomiting (RR: 1.08, 95% CI: 0.76 - 1.54; P = 0.65), pruritus (RR: 0.77, 95% CI: 0.51 - 1.17; P = 0.22), and bradycardia (RR: 4.45, 95% CI: 0.97 - 20.36; P = 0.05) were not significantly increased. The sensory (WMD: 23.15, 95% CI: 7.83 - 38.48; P = 0.003), and motor block duration (WMD: 24.29, 95% CI: 16.36 - 32.23; P = 0.00001) and the duration of spinal anesthesia (WMD: 29.24, 95% CI: 13.61 - 44.87; P = 0.0002) were significantly in favor of MgSO4.

Conclusion: Intrathecal MgSO4 as an adjuvant to bupivacaine was associated with a significantly lower risk of shivering without causing any increase in other adverse drug events in patients undergoing elective cesarean section. Efficacy outcomes were also appreciated. Larger studies should be able to confirm this hypothesis.

择期剖宫产患者鞘内硫酸镁辅助布比卡因用于脊髓麻醉的不良药物事件观察:一项荟萃分析。
导读:今天,剖宫产手术的数量急剧增加。最新的科学报告显示,硫酸镁(MgSO4)具有良好的麻醉效果。在本分析中,我们旨在系统地比较鞘内MgSO4作为布比卡因脊髓麻醉辅助剂用于择期剖宫产患者的不良药物事件。方法:检索MEDLINE、EMBASE、Web of Science、谷歌scholar、http://www.Clinicaltrials: gov和Cochrane数据库,检索比较选择性剖宫产患者鞘内MgSO4辅助布比卡因用于脊髓麻醉观察到的不良药物事件的相关出版物。本分析采用RevMan 5.4版软件进行数据分析。采用具有95%置信区间(CI)的风险比(RR)来表示二分类数据的分析,而采用具有95% CI的加权平均差(WMD)来表示连续数据的结果。采用Q统计量和I2统计量检验评价异质性。结果:11项研究共纳入895名参与者,其中466名患者被分配到鞘内MgSO4, 429名参与者被分配到对照组。本分析的主要结果显示,鞘内MgSO4作为布比卡因的辅助剂与发抖的风险显著降低相关(RR: 0.63, 95% CI: 0.48 - 0.83;P = 0.001)。此外,低血压的风险(RR: 1.11, 95% CI: 0.86 - 1.44;P = 0.40)、恶心和呕吐(RR: 1.08, 95% CI: 0.76 - 1.54;P = 0.65)、瘙痒(RR: 0.77, 95% CI: 0.51 ~ 1.17;P = 0.22),心动过缓(RR: 4.45, 95% CI: 0.97 - 20.36;P = 0.05)无显著升高。感官(WMD: 23.15, 95% CI: 7.83 - 38.48;P = 0.003)和运动阻滞持续时间(WMD: 24.29, 95% CI: 16.36 - 32.23;P = 0.00001)和脊髓麻醉时间(WMD: 29.24, 95% CI: 13.61 ~ 44.87;P = 0.0002)显著有利于MgSO4。结论:鞘内MgSO4作为布比卡因的辅助剂可以显著降低选择性剖宫产患者的寒战风险,而不会增加其他药物不良事件的发生。疗效结果也得到赞赏。更大规模的研究应该能够证实这一假设。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology PHARMACOLOGY & PHARMACYTOXICOLOGY&nb-TOXICOLOGY
CiteScore
4.80
自引率
0.00%
发文量
87
审稿时长
12 weeks
期刊介绍: BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信